Ardelyx Collects $17.6M

Xconomy San Francisco — 

Fremont, CA-based Ardelyx, which is developing small-molecule drugs to treat gastrointestinal disorders, has raised $17.6 million in Series B funding in a round that could go as high as $22.3 million, according to a regulatory filing last week. Ardelyx’s previous investors include CMEA Capital and New Enterprise Associates (NEA).